Study of VX-770 and Rifampin in Healthy Male Subjects

Completed · Phase 1

Conditions studied: Cystic Fibrosis

In brief

The objectives of this study are to evaluate the effects of multiple doses of rifampin on the single-dose pharmacokinetics of VX 770.

Key facts

Study ID

NCT01018368

Run by

Vertex Pharmaceuticals Incorporated

People needed

24

Starts

2009-11-01

Expected to finish

2010-03-01

Last updated by the study team

2010-05-10

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Subject must be male and between 18 and 55 years of age
• Subject must have a body mass index (BMI) from 18 to 30 kg/m2

You may not qualify if…

• History of any illness or condition that, in the opinion of the investigator might confound the results of the study or pose an additional risk in administering study drug to the subject
• Subjects who have active tuberculosis, human immunodeficiency virus, hepatitis C, or active hepatitis B

Where it is running

• Study site — Daytona Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.